Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 2 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

NCT05143177 is registered in ClinicalTrials.gov with REDNVIA Co., Ltd. as lead sponsor.

NCT NCT05143177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05143177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 2 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Lead sponsor
REDNVIA Co., Ltd.
Phase
Phase 2/3
Overall status
Terminated
Start date
June 27, 2022
Completion date
March 26, 2026
Enrollment
486 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

calcific aortic valve disease